Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A(2)

 
Το τεκμήριο παρέχεται από τον φορέα :
Πανεπιστήμιο Ιωαννίνων
Αποθετήριο :
Ιδρυματικό Αποθετήριο Ολυμπιάς
δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*
κοινοποιήστε το τεκμήριο



Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A(2) (EN)

Saougos, V. G. (EN)

Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας (EL)
Saougos, V. G. (EN)

Objective-Lipoprotein- associated phospholipase A(2) (Lp-PLA(2)) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA(2) activity and mass. Methods and Results-In 50 patients with Type IIA dyslipidemia were administered rosuvastatin (10 mg daily), whereas in 50 Type IIA dyslipidemic patients exhibiting intolerance to previous statin therapy were administered ezetimibe as monotherapy (10 mg daily). Fifty patients with Type IV dyslipidemia were given micronised fenofibrate (200 mg daily). Low- and high-density lipoprotein (LDL and HDL, respectively) subclass analysis was performed electrophoretically, whereas lipoprotein subfractions were isolated by ultracentrifugation. Ezetimibe reduced plasma Lp-PLA(2) activity and mass attributable to the reduction in plasma levels of all LDL subfractions. Rosuvastatin reduced enzyme activity and mass because of the decrease in plasma levels of all LDL subfractions and especially the Lp-PLA(2) on dense LDL subfraction (LDL-5). Fenofibrate preferentially reduced the Lp-PLA(2) activity and mass associated with the VLDL+IDL and LDL-5 subfractions. Among studied drugs only fenofibrate increased HDL-associated Lp-PLA(2) (HDL-Lp-PLA(2)) activity and mass attributable to a preferential increase in Lp-PLA(2) associated with the HDL-3c subfraction. Conclusion-Ezetimibe, rosuvastatin, and fenofibrate reduce Lp-PLA(2) activity and mass associated with the atherogenic apoB-lipoproteins. Furthermore, fenofibrate improves the enzyme specific activity on apoB-lipoproteins and induces the HDL-Lp-PLA(2). The clinical implications of these effects remain to be established. (EN)

hyperlipidemia (EN)

Πανεπιστήμιο Ιωαννίνων (EL)
University of Ioannina (EN)

Arteriosclerosis Thrombosis and Vascular Biology (EN)

2007

<Go to ISI>://000249587000024

American Heart Association, Inc. (EN)



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.